Cytokinetics (CYTK) analyst forecast and price target
Analyst forecast
Consensus of 23 analyst ratings
Based on 7 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| RBC Capital | Maintained | Outperform | $113.00 from $112.00 | Oct 8, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $140.00 | Aug 31, 2026 |
| JP Morgan | Maintained | Overweight | $103.00 from $97.00 | Aug 13, 2026 |
| Barclays | Maintained | Overweight | $110.00 from $95.00 | Aug 13, 2026 |
| Truist Securities | Maintained | Buy | $112.00 from $106.00 | Aug 10, 2026 |
| Needham | Maintained | Buy | $112.00 from $102.00 | Aug 7, 2026 |
| Citizens | Maintained | Market Outperform | $110.00 from $105.00 | Aug 7, 2026 |
| RBC Capital | Maintained | Outperform | $112.00 from $117.00 | Aug 7, 2026 |
| RBC Capital | Maintained | Outperform | $117.00 from $119.00 | Jul 7, 2026 |
| UBS | Upgraded | Neutral → Buy | $115.00 from $69.00 | Jun 29, 2026 |
| Mizuho | Maintained | Outperform | $118.00 from $100.00 | Jun 24, 2026 |
| Needham | Maintained | Buy | $102.00 | Jun 17, 2026 |
| Citigroup | Initiated Coverage | Buy | $99.00 | May 19, 2026 |
| JP Morgan | Maintained | Overweight | $97.00 from $92.00 | May 12, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $140.00 from $136.00 | May 11, 2026 |
| Wells Fargo | Maintained | Overweight | $105.00 from $95.00 | May 7, 2026 |
| RBC Capital | Maintained | Outperform | $119.00 from $101.00 | May 6, 2026 |
| Morgan Stanley | Maintained | Overweight | $103.00 from $90.00 | May 6, 2026 |
| Stifel | Maintained | Buy | $108.00 from $98.00 | May 6, 2026 |
| Needham | Maintained | Buy | $102.00 from $85.00 | May 5, 2026 |
Frequently asked questions
What is the price target for CYTK stock?
The average 12-month analyst price target for Cytokinetics (CYTK) is $114.29, with a high estimate of $140.00 and a low of $103.00, across 7 analysts.
Is CYTK a buy, sell, or hold?
Analysts covering Cytokinetics currently average a Buy rating: 21 buy, 2 hold and 0 sell, from 23 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for CYTK?
The average price target of $114.29 implies 82.01% upside from the last price of $62.79.
What is the latest analyst rating on CYTK?
On Oct 8, 2026, RBC Capital maintained Cytokinetics at Outperform with a price target of $113.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.